Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASGCT 2021 | Complement inhibition for the treatment of TA-TMA

Eleni Gavriilaki, MD, PhD, George Papanikolaou Hospital, Thessaloniki, Greece, discusses the role of complement activation in the pathophysiology of transplant-associated thrombotic microangiopathy (TA-TMA), a severe complication of hematopoietic stem cell transplantation (HSCT), and research into complement inhibitors such as eculizumab for the treatment of patients with TA-TMA. At ASGCT 2021, Dr Gavriilaki presented research into functional assays for the diagnosis of TA-TMA, as well as therapeutic data evaluating complement inhibition, which has resulted in improved survival in selected TA-TMA patient populations. The MASP-2 inhibitor narsoplimab is also currently being investigated in clinical trials for TA-TMA. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.


E.G. has consulted for Alexion and Omeros Pharmaceuticals, Inc.